TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05636800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swift System
Description: Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered
Study: NCT05539989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002 Vaccine
Description: 0.1 mL (2-8x10\^5 CFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: 0.1mL (0.075 Mycobacterium bovis)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mL (sodium chloride for injection 0.9%)
Study: NCT05141877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
Study: NCT05033405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEURO-LINGUISTIC PROGRAMMING (NLP)
Description: ● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
Study: NCT06210360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m² continuous IV infusion in 46 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m² continuous IV infusion in 46 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 400 mg/m² on Day 1 of a 14 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV
Description: 400 mg/m² on Day 1 of a 14 day cycle
Study: NCT05723471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptative Physical Activity
Description: 12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
Study: NCT04944680

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation therapy
Description: Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery therapy
Description: Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation and motor imagery therapy
Description: The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
Study: NCT06297785

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gut-directed hypnotherapy
Description: Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
Study: NCT04870697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT intervention
Description: The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care in this study setting includes providing general information, education, psychological support, and consultation.
Study: NCT05772585

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
Study: NCT05170867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hafnia alvei HA4597™
Description: One capsule of probiotic supplement, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the dietary supplement contain 5x107 CFU of Hafnia alvei HA4597™, 5 mg of zinc and 20 μg of chromium.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the placebo contain 5 mg of zinc and 20 μg of chromium.
Study: NCT04546828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, and Nab-Paclitaxe
Description: * Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days .
Study: NCT06476054

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optimal timing for laparoscopic cholecystectomy
Description: To compare early and late cholecystectomy after cholecystostomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optimal timing for laparoscopic cholecystectomy
Description: To compare early and late cholecystectomy after cholecystostomy.
Study: NCT05600075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: microneedling with topical glycolic acid 35%.
Description: 15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: microneedling with topical human insulin solution.
Description: 15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
Study: NCT05282914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UI058
Description: UI058 1Tab/day for 7days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of UIC202004
Description: UIC202004 1Tab/day for 7days
Study: NCT05908643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pTTL
Description: pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
Study: NCT04033588

Intervention type: DEVICE
Group type: OTHER
Intervention: Freedom® Total Knee System
Description: To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
Study: NCT06134011

Intervention type: OTHER
Intervention: Without any intervention
Description: There were no special interventions for the two groups.

Intervention type: OTHER
Intervention: Without any intervention
Description: There were no special interventions for the two groups.
Study: NCT05884801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1103
Description: Oral dose
Study: NCT05546619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC+tislelizumab + targeted therapy
Description: Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
Study: NCT04236544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PExMS and DECIMS-Wiki
Description: The intervention consists of an information provision on immunotherapies as a combination of factual and experiential information. PExMS is a multimedia website providing patient experiences with MS in everyday life and with therapies illustrated by video, audio and text files of 48 persons with multiple sclerosis. The development of the intervention followed largely recommendation for standardised qualitative research provided by international DIPEx (Database of Individual Patients' Experience of illness) association, which use standardised qualitative research methods to provide 'balanced' information from original interview data. Data for the website was generated in a qualitative interview study with relapsing remitting multiple sclerosis patients across Germany. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DECIMS-Wiki
Description: The active comparator is DECIMS-Wiki, which is an evidence-based online information platform. It is considered to be excellent factual information about immunotherapies for multiple sclerosis.
Study: NCT04857697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, stool, and tissue samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study: NCT05617222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: 5 days of strict bed rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: 5 days of strict bed rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Unilateral neuromuscular electrical stimulation (m. Quadriceps)
Study: NCT05387447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational Voice Assistant-Enhanced
Description: Interactive routine is based on tailoring to the participants type of pain and personality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational Voice Assistant-Standard
Description: Interactive routine is a basic interaction with the voice assistant.
Study: NCT05685615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100 plus Polymyxin B
Description: Rifabutin for Infusion plus Polymyxin B for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100 plus Polymyxin B
Description: Rifabutin for Infusion plus Polymyxin B for Injection
Study: NCT05433623

Intervention type: PROCEDURE
Intervention: Surgery
Description: It will be documented if the patient underwent surgery for their vascular issue
Study: NCT06047951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic RadioSurgery (SRS)
Description: All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~* The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~* Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~* Only one aneurysm will be treated per patient~* The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~* A prescription dose of 25 Gy at the margin of the target will be used~* The maximal dose on optic pathways will be kept below 10 Gy~* The brainstem 12-Gy volume will be kept below 1cc
Study: NCT06070220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: traditional occupational therapy intervention and client-centered intervention
Description: Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional occupational therapy intervention
Description: The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~1. st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~2. nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~3. rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided.
Study: NCT05122598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COT
Description: The COT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
Study: NCT05554120

Intervention type: OTHER
Intervention: Supermarket tobacco sales ban
Description: In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
Study: NCT05685615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: The best avaialble antibiotic therapy to treat CRAB
Study: NCT05554120

Intervention type: OTHER
Intervention: Supermarket tobacco sales ban
Description: In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.

Intervention type: OTHER
Intervention: Supermarket tobacco sales ban
Description: In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
Study: NCT05223595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab
Description: Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily.
Study: NCT05685615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: The best avaialble antibiotic therapy to treat CRAB
Study: NCT04539964

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Implant Procedure
Description: The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant Procedure
Description: The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conventional Synthetic DMARD
Description: All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional Synthetic DMARD
Description: All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active stimulation
Description: Active stimulation for 1 min once per day

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-active stimulation
Description: Non-active stimulation for 1 min once per day
Study: NCT06533449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Couplet Care Bassinet
Description: Couplet Care Bassinet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bassinet
Description: Standard Bassinet
Study: NCT05185947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: Intraperitoneal (IP) paclitaxel will be dosed at 60 mg/m2 to be infused over 1 hour on Day 1 of each 3-week cycle; participants with unresectable, but stable or responding disease after C1 through C3 will dose increase IP paclitaxel to 80 mg/m2 for Cycles 4-6. Intravenous (IV) paclitaxel will be infused over 1 hour on Day 2 of the first week of Cycle 1, followed by Day 1 of the subsequent treatment weeks; IV paclitaxel will be dosed at 60 mg/m2 for Week 1 of Cycle 1 and, if tolerated, at 80 mg/m2 for subsequent treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Oral nilotinib will be dosed at 300 mg twice daily. Nilotinib will be administered continually from the loading dose (Day -4) leading up to laparoscopy #2 onward.
Study: NCT06540417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External trigeminal nerve stimulation
Description: The stimulation parameters were set to 120Hz, 250μs, 30s ON-30s OFF, with the intensity adjusted for patient comfort.
Study: NCT04092647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: Ashwagandha 350 mg po BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 350 mg po BID
Study: NCT05436509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR CD19/79b T cells
Description: Infusion of bi-4SCAR-CD19/79b T cells at 10\^6 cells/kg body weight via IV
Study: NCT04661384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Description: Given ICV
Study: NCT04660188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative care arm
Description: Study participants will be cared for by a team of healthcare professionals; an oncologist, a PCP and a pharmacist navigator.
Study: NCT04850560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
Description: CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
Study: NCT05471583

Intervention type: OTHER
Intervention: Main group
Description: no intervention; observational only